CORT
Corcept Therapeutics Incorporated · Healthcare · Medical - Pharmaceuticals
Momentum inputs (comparable managers):
holder breadth +7.7% ·
share flow -4.2% ·
net new positions +7.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 115 | +10 | 52.54M | $4.56B | +17 | −6 |
| Q1 2026 | 107 | -4 | 51.80M | $2.09B | +8 | −13 |
| Q4 2025 | 112 | 0 | 56.18M | $1.96B | +1 | — |
| Q3 2025 | 18 | -2 | 41.55M | $3.45B | +1 | −4 |
| Q2 2025 | 18 | +1 | 38.50M | $2.83B | +1 | — |
| Q1 2025 | 14 | +1 | 15.71M | $1.80B | +1 | — |
| Q4 2024 | 13 | 0 | 16.40M | $826.20M | — | — |
| Q3 2024 | 12 | -1 | 13.66M | $632.44M | — | −1 |
| Q2 2024 | 13 | — | 13.78M | $447.82M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 6.14M | -0.9% | $701.66M | 1.1% | ▼ Trim | 4 | SEC ↗ |
| 2 | State Street Global Advisors ✦ (passive) | 3.40M | -4.1% | $388.57M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.26M | +9.3% | $258.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 2.26M | +9.3% | $258.99M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 1.49M | -9.3% | $170.44M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 6 | Norges Bank ✦ (passive) | 848.90K | +1.7% | $96.96M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 700.26K | -21.0% | $79.98M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 700.26K | -21.0% | $79.98M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 9 | Millennium Management ✦ | 281.96K | -44.5% | $32.21M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 253.03K | -8.5% | $28.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 253.03K | -8.5% | $28.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 253.03K | -8.5% | $28.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | AQR Capital Management ✦ | 253.03K | -8.5% | $28.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 14 | AQR Capital Management ✦ | 253.03K | -8.5% | $28.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | Two Sigma Investments ✦ | 180.15K | -11.1% | $20.58M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 64.89K | +18.5% | $7.41M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 17 | Wellington Management ✦ | 35.51K | -5.9% | $4.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 18 | Wellington Management ✦ | 35.51K | -5.9% | $4.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 19 | Wellington Management ✦ | 35.51K | -5.9% | $4.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 20 | Wellington Management ✦ | 35.51K | -5.9% | $4.06M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Citadel Advisors ✦ | 28.26K | -75.5% | $3.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Citadel Advisors ✦ | 28.26K | -75.5% | $3.23M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 23 | Gotham Asset Management ✦ | 17.42K | -9.0% | $1.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | Marshall Wace ✦ | 5.16K | New | $589,376 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $589,376 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 347 holders, 79.01M shares, $2.83B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 4.98K sh · $585,478
Director · 91.17K sh · $10.78M
Director · 7.05K sh · $838,710
Director · 400 sh · $47,855
Officer · 10.00K sh · $1.16M
Director · 3.05K sh · $337,341
Director · 4.67K sh · $520,214
Director · 2.28K sh · $256,706
Officer · 3.66K sh · $419,491
Officer · 11.53K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology